Trial Profile

A Clinical Trial to Evaluate Ridinilazole for the Treatment of C. Difficile Infection in Adolescent Patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jan 2020 New trial record
23 Jan 2020 According to a Summit Therapeutics media release, this adolescent clinical trial is expected to support a New Drug Application for ridinilazole and also form part of a package of work with the potential to provide an additional six months market exclusivity for ridinilazole in the US and Europe.
23 Jan 2020 According to a Summit Therapeutics media release, the Biomedical Advanced Research and Development Authority (BARDA) has expanded its award for the clinical and regulatory development of ridinilazole for the treatment of C. difficile infection by $8.8 million.The additional funding is being provided to support this new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com